Gilead Sciences Q1 Earnings Due as It Bets Beyond HIV Drugs

Gilead Sciences spent most of its history making billions from one category of disease. Now it is betting billions more to ensure that category does not define its entire future.

The American biopharmaceutical giant’s shares slipped 1.36% on Thursday, losing $1.85 to settle at $134.45, as investors waited for first-quarter earnings scheduled after US market close. For anyone holding Gilead positions through an Indian global mutual fund or a direct US stock platform, the dip was a minor tremor on an otherwise decent year. The stock is up about 10.7% in 2026.

Wall Street set the bar at earnings of $1.91 per share, a 5.5% improvement over the same quarter last year. Revenue expectations sat at $6.92 billion, roughly 3.7% above year-ago figures. Gilead has cleared earnings forecasts every single quarter over the past two years, and beaten revenue targets in 88% of reporting periods. The historical record points toward another comfortable beat.

But the story that matters sits well beyond the quarterly scorecard.

The HIV dependency problem

Gilead built its empire on HIV drugs. Its antiviral medicines remain among the most prescribed globally, and the HIV franchise generates the steady cash flows that fund everything else. The problem is that a business this concentrated in one therapeutic category carries structural risk. Patent cliffs eventually arrive. Newer drug classes compete for patients. Gilead’s own leadership clearly agrees the company needs a different shape.

Chief Executive Officer Daniel O’Day has spent the past three months writing enormous cheques aimed at reshaping that story. In February, Gilead agreed to acquire Arcellx Inc., a cancer-focused biotech, for approximately $7.8 billion. In March, it added Ouro Medicines, an autoimmune therapy company, for up to $2.18 billion. Then, last month, it reached a deal to acquire Tubulis GmbH, a German biotechnology firm, for up to $5 billion.

Three acquisitions. One quarter. A combined price tag approaching $15 billion. That is not portfolio tinkering. That is a company telling the market it intends to be fundamentally different within five years.

What an ADC is, and why the whole industry wants one

The Tubulis deal is the most technically interesting of the three, and it centres on a class of drug that the cancer treatment world is watching very closely right now.

Antibody-drug conjugates (ADCs) work by attaching a cancer-killing chemical compound to an antibody that specifically seeks out cancer cells. Think of it as a guided missile compared to traditional chemotherapy, which works more like carpet bombing. The ADC homes in, delivers its payload directly to the tumour, and largely spares the surrounding healthy tissue that conventional drugs destroy along the way.

Pfizer’s acquisition of Seagen, an ADC specialist, for $43 billion in 2023 signalled how seriously the pharmaceutical industry values this technology platform. Gilead already markets Trodelvy, an ADC approved for breast cancer. Tubulis brings pipeline candidates currently in clinical trials for lung and ovarian cancers, among other solid tumours.

The ovarian cancer market alone is projected by industry analysts to reach $5.6 billion globally by 2030. Tubulis’s drug candidates would compete in that space against AstraZeneca and Eli Lilly. Upon deal closure, Tubulis will operate as a dedicated ADC research unit inside Gilead, using its Munich headquarters as its primary scientific base.

O’Day called the Tubulis acquisition “a significant milestone in Gilead’s progress in oncology.” From a strategic standpoint, it fills a meaningful gap. Gilead now holds cancer drug candidates spanning breast, lung, and ovarian cancers, plus an antibody platform to develop more.

What the numbers mean for Indian investors watching this stock

For an investor who holds Gilead through a US direct investment platform, or whose global equity mutual fund carries a Gilead position, the near-term picture is relatively straightforward. Gilead’s 2026 guidance projects non-GAAP earnings between $8.45 and $8.85 per share. That guidance midpoint came in slightly below some analyst expectations when it was first announced, which partly explains why the stock has not run harder despite its solid track record.

The market is effectively pricing in a question mark: can Gilead actually execute the pivot to oncology, or will it remain an HIV story with expensive side bets that take years to pay off?

The skepticism is fair. Three acquisitions totalling $15 billion do not automatically produce blockbuster drugs. Drug development timelines are long. Clinical trials fail frequently. Tubulis’s candidates are still in early-to-mid clinical stages, meaning years of trial work remain before any commercial product reaches patients. Gilead is buying potential, not finished medicine.

What Thursday’s earnings will clarify is whether the core HIV business can keep generating the cash that finances this ambition. If revenue and margins hold firm, the transformation strategy becomes more credible. If the core shows any strain, the multi-billion-dollar cancer bets start carrying more risk for shareholders.

Why this matters beyond portfolio returns

Indian pharmaceutical companies are not passive observers to this global wave of oncology acquisitions. Generic drug makers in India watch ADC development closely. The patents on early-generation ADCs will not last forever, and Indian generics have a well-established history of entering markets aggressively once those windows open. The science being built in Munich research labs today becomes the generic battleground in India within a decade.

The more immediate relevance, though, is for Indian patients navigating cancer diagnoses. Trodelvy, Gilead’s existing ADC for breast cancer, is available in select markets including India, though at significant cost. As Gilead’s pipeline matures and additional ADCs gain regulatory approval across markets, the pressure on pricing and access typically increases, particularly as Indian health insurance frameworks expand their oncology coverage.

When the world’s largest pharmaceutical companies are willing to spend $43 billion and $15 billion-plus on next-generation cancer therapies within two years of each other, they are telling us something important about where the most meaningful medical progress of the next decade is expected to come from. Cancer, not infectious disease, is increasingly where the drug development capital flows.

For ordinary families dealing with cancer diagnoses in India, that is a signal with real-world implications over the years ahead, even if the path from a Munich research lab to an affordable pharmacy shelf in Nagpur or Thrissur is a long and uncertain one. The science advances. The economics catch up eventually.